We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$957M
AUM Growth
+$1.08M
Cap. Flow
-$9.87M
Cap. Flow %
-1.03%
Top 10 Hldgs %
32.99%
Holding
140
New
9
Increased
34
Reduced
55
Closed
6

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$11.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$9.5M
3
ONC
BeOne Medicines Ltd
ONC
+$9.49M
4
INCY icon
Incyte
INCY
+$8.91M
5
CELG
Celgene Corp
CELG
+$8.11M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$20.7M
2
GILD icon
Gilead Sciences
GILD
+$16.8M
3
ABMD
Abiomed Inc
ABMD
+$10.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$8.6M
5
ABBV icon
AbbVie
ABBV
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Financials 0.41%
3 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.31B
$4.46M 0.47%
4,980
-3,220
-39% -$1.9M
NBIX icon
52
Neurocrine Biosciences
NBIX
$17.2B
$4.23M 0.44%
54,500
-1,500
-3% -$102K
BMRN icon
53
BioMarin Pharmaceuticals
BMRN
$11.5B
$4.02M 0.42%
45,050
-3,750
-8% -$326K
RMD icon
54
ResMed
RMD
$28.9B
$3.98M 0.42%
47,000
– –
AET
55
DELISTED
Aetna Inc
AET
$3.97M 0.41%
22,000
-34,700
-61% -$5.96M
ESRX
56
DELISTED
Express Scripts Holding Company
ESRX
$3.69M 0.39%
49,500
– –
JNJ icon
57
Johnson & Johnson
JNJ
$609B
$3.63M 0.38%
26,000
-5,500
-17% -$766K
XRAY icon
58
Dentsply Sirona
XRAY
$2.81B
$3.59M 0.37%
54,500
– –
TFX icon
59
Teleflex
TFX
$5.96B
$3.48M 0.36%
14,000
+3,800
+37% +$955K
LGND icon
60
Ligand Pharmaceuticals
LGND
$6.08B
$3.48M 0.36%
40,716
-37,350
-48% -$3.24M
BLUE
61
DELISTED
bluebird bio
BLUE
$3.4M 0.36%
1,475
-463
-24% -$940K
MOH icon
62
Molina Healthcare
MOH
$11.7B
$3.34M 0.35%
43,500
– –
GNMK
63
DELISTED
GenMark Diagnostics, Inc
GNMK
$3.23M 0.34%
773,677
+250,000
+48% +$1.5M
HSIC icon
64
Henry Schein
HSIC
$10B
$3M 0.31%
54,825
+6,375
+13% +$370K
LABU icon
65
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
$2.99M 0.31%
+1,920
New +$2.94M
CERN
66
DELISTED
Cerner Corp
CERN
$2.96M 0.31%
44,000
-30,500
-41% -$2.11M
PRGO icon
67
Perrigo
PRGO
$1.48B
$2.88M 0.3%
33,000
-13,468
-29% -$1.16M
SGEN
68
DELISTED
Seagen Inc. Common Stock
SGEN
$2.86M 0.3%
53,500
+8,500
+19% +$497K
ALKS icon
69
Alkermes
ALKS
$8.79B
$2.83M 0.3%
51,700
-4,400
-8% -$225K
ALNY icon
70
Alnylam Pharmaceuticals
ALNY
$35.7B
$2.81M 0.29%
22,100
-53,493
-71% -$6.72M
AGN
71
DELISTED
Allergan plc
AGN
$2.7M 0.28%
16,500
-4,000
-20% -$718K
UTHR icon
72
United Therapeutics
UTHR
$22.7B
$2.54M 0.27%
17,200
-4,400
-20% -$559K
AGIO icon
73
Agios Pharmaceuticals
AGIO
$2.36B
$2.34M 0.24%
40,900
-4,100
-9% -$258K
MCK icon
74
McKesson
MCK
$98.5B
$2.15M 0.22%
13,800
-4,200
-23% -$622K
PTLA
75
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.11M 0.22%
43,350
+11,850
+38% +$599K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2017 Portfolio in Review

As of Q4 2017, Bellevue Group held 140 positions worth $957M, up 0.11% from $956M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group's Q4 2017 filing shows 9 new, 34 increased, 55 reduced and 6 closed positions. Its largest new stake was Supernus Pharmaceuticals: 240,400 shares worth $9.58M. The largest sale was Amgen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Group's largest Q4 2017 buy was Supernus Pharmaceuticals: 240,400 shares worth $9.58M.
  • Bellevue Group added most to DexCom in Q4 2017, an estimated $11.5M increase.
  • Bellevue Group's biggest Q4 2017 reduction was Amgen, cutting an estimated $20.7M.
  • Bellevue Group fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $8.6M.
  • Bellevue Group's ten largest holdings make up 33% of its $957M portfolio in Q4 2017.
  • Bellevue Group opened 9 new positions and closed 6 in Q4 2017.
  • Bellevue Group's portfolio value rose 0.11% quarter-over-quarter to $957M.

Based on Bellevue Group's 13F filing for Q4 2017, filed 14 Feb 2018.